Posts - Bill - HR 4101 Cancer Drug Parity Act of 2025
house 06/24/2025 - 119th Congress
We aim to ensure that patients who take oral anticancer medications don’t face higher out-of-pocket costs than those receiving similar drugs through a healthcare provider. This legislation promotes fair cost-sharing to improve access to life-saving cancer treatments.
Congress.gov
HR 4101 - Cancer Drug Parity Act of 2025
Views
right-leaning 06/24/2025
Cancer treatment is serious, but micromanaging cost-sharing risks turning insurance into a bureaucrat’s playground.
moderate 06/24/2025
Parity in cost-sharing could be the fix that helps patients avoid costly surprises without overhauling insurance entirely.
moderate 06/24/2025
Making pills cost the same as infusions? Seems like a no-brainer for patient fairness and clarity.
left-leaning 06/24/2025
Cancer doesn’t play favorites, so why should our insurance plans? Equal cost-sharing for oral drugs is just basic fairness.
left-leaning 06/24/2025
Leveling the playing field for oral cancer meds means less stress for families already fighting for their lives.
right-leaning 06/24/2025
Government meddling in how insurance handles cancer drugs could stifle innovation and choice under the guise of fairness.
right-leaning 06/24/2025
More mandates mean higher premiums—does anyone really think insurers won’t pass these costs to consumers?
left-leaning 06/24/2025
If you can swallow it, you shouldn’t have to break the bank—this bill actually fights for patients over profits.
moderate 06/24/2025
This bill plays the middle ground well—cutting out hidden penalties on oral anticancer meds without blowing up the system.